Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH6QAI)

Drug Name

FK778 Drug Info

Synonyms

Manitimus; FK 778; HMR 1715; MNA 715; Malononitrilamide 715; X 920715; FK-778; HMR-1715; MNA-715; MNA-X 920715; Malononitrilamide-715; X-920715; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxohept-6-ynenitrile; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid

Indication

Disease Entry	ICD 11	Status	REF
Kidney/heart transplant rejection	NE84	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 70683056
TTD Drug ID: DMH6QAI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dihydroorotate dehydrogenase (DHODH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[3]
Vidofludimus	DM0POWG	Inflammatory bowel disease	DD72	Phase 2	[4]
BREQUINAR	DMKGM42	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[5]
BAY2402234	DMRL6W5	Myeloid leukaemia	2B33.1	Phase 1	[6]
LAS-186323	DMV80DP	Multiple sclerosis	8A40	Phase 1	[7]
HR325	DM51GZS	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dihydroorotate dehydrogenase (DHODH)	TTLVP78	PYRD_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
2	Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation. 2003 Dec 15;76(11):1627-9.
3	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4	Company report (4SC)
5	DOI: 10.1203/00006450-198807000-00137
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of Aslanpharma.
8	In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42.